Well, the rida endometrial trial showed over 100% improvement in pts who achieved stable disease vs the control arm. The benefit has to be coming from somewhere, lol. Furthermore, the CBR that the majority of the pts in the everolimus trial was from....wait for it....achieving stable disease.
Also, your post to the contrary, rida appears to be far more tolerable in this setting than everolimus.
News 
Market Data 
Discover 
